Neuronetics (STIM) Projected to Post Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is expected to be releasing its earnings data before the market opens on Tuesday, March 4th. Analysts expect Neuronetics to post earnings of ($0.26) per share and revenue of $18.98 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Neuronetics Price Performance

Shares of STIM opened at $4.46 on Tuesday. The business’s 50-day moving average is $2.61 and its two-hundred day moving average is $1.53. The company has a market capitalization of $135.35 million, a P/E ratio of -3.63 and a beta of 2.16. Neuronetics has a fifty-two week low of $0.52 and a fifty-two week high of $5.07. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Insider Buying and Selling

In other news, CFO Stephen Furlong sold 17,307 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the transaction, the chief financial officer now owns 454,420 shares in the company, valued at $1,867,666.20. This trade represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP William Andrew Macan sold 12,175 shares of Neuronetics stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total transaction of $46,630.25. Following the sale, the executive vice president now directly owns 388,647 shares in the company, valued at approximately $1,488,518.01. This trade represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,125 shares of company stock valued at $348,876. 9.80% of the stock is owned by company insiders.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.